Popular GLP-1 drug may slow down biological aging, analysis indicates
medicalxpress.com
Glucagon-like peptide-1 (GLP-1) receptor agonist medications have gained widespread attention for effectively treating obesity, lowering blood sugar and decreasing the risk of cardiovascular disease. Some researchers have proposed that these drugs may also influence the biology of aging, but direct evidence in humans has remained limited.

Wow, what can’t these GLP-1 drugs do? Not only making you thin, but boosts for cardiovascular health, blood pressure & inflammation related illness & apparently improving outlooks for some cancers, too.

As they are now entering their generic era in territories around the world (India, Brazil & Canada in 2026), we should start to see dramatic health improvements in these countries.

  • Grimy@lemmy.worldEnglish
    2·
    2 小时前

    Now, a new study provides the first randomized, placebo-controlled clinical evidence that semaglutide, a widely used GLP-1 drug, slows down the accumulation of biological aging markers in the DNA of adults with HIV.